In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution.

Autor: Angheloiu AA; Temple University, Philadelphia, PA, USA., Tan Y; Mass Spectrometry Facility, University of Massachusetts Medical School, Shrewsbury, MA, USA.; Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA., Ruse C; New England Biolabs, Ipswich, MA, USA., Shaffer SA; Mass Spectrometry Facility, University of Massachusetts Medical School, Shrewsbury, MA, USA.; Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA., Angheloiu GO; Cardiology Department, University of Pittsburgh Medical Center, 700 High Street, Williamsport, PA, 17701, USA. angheloiug@upmc.edu.
Jazyk: angličtina
Zdroj: Drugs in R&D [Drugs R D] 2020 Sep; Vol. 20 (3), pp. 217-223.
DOI: 10.1007/s40268-020-00308-1
Abstrakt: Background and Objective: Based on previous experience of sorbent-mediated ticagrelor, dabigatran, and radiocontrast agent removal, we set out in this study to test the effect of two sorbents on the removal of edoxaban, a factor Xa antagonist direct oral anticoagulant.
Methods: We circulated 100 mL of edoxaban solution during six first-pass cycles through 40-mL sorbent columns (containing either CytoSorb in three passes or Porapak Q 50-80 mesh in the remaining three passes) during experiments using human plasma and 4% bovine serum albumin solution as drug vehicles. Drug concentration was measured by liquid chromatography-tandem mass spectrometry.
Results: Edoxaban concentration in two experiments performed with human plasma dropped from 276.8 to 2.7 ng/mL and undetectable concentrations, respectively, with CytoSorb or Porapak Q 50-80 mesh (p = 0.0031). The average edoxaban concentration decreased from 407 ng/mL ± 216 ng/mL to 3.3 ng/mL ± 7 ng/mL (p = 0.017), for a removal rate of 99% across all six samples of human plasma (two samples) and bovine serum albumin solution (four samples). In four out of the six adsorbed samples, the drug concentrations were undetectable.
Conclusion: Sorbent-mediated technology may represent a viable pathway for edoxaban removal from human plasma or albumin solution.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje